利奥西胍治疗早期弥漫性皮肤型系统性硬化症患者(RISE-SSc):2b期随机安慰剂对照试验的开放标签长期扩展研究
RISE-SSc长期扩展研究纳入完成52周双盲期的早期弥漫性皮肤型系统性硬化症患者,原利奥西胍组继续用药,原安慰剂组换用利奥西胍并调整至2.5 mg每日三次。87例患者中82例(94%)发生不良事件,多数为轻中度,间质性肺病患者中肺部相关严重不良事件未增加,未观察到新的安全性信号。
要点
- 长期扩展研究未观察到利奥西胍新的安全性信号。
- 87例中82例(94%)发生不良事件,66例(76%)为轻中度。
- 间质性肺病患者中肺部相关严重不良事件未增加。
核心结论
- 早期弥漫性皮肤型系统性硬化症患者长期使用利奥西胍未观察到新的安全性信号。
研究设计与样本
- RISE-SSc 2b期随机安慰剂对照试验的开放标签长期扩展研究,患者于2015年1月15日至2016年12月8日入组。
- 完成52周随机双盲期的患者进入长期扩展,原利奥西胍组继续治疗,原安慰剂组换用利奥西胍并经10周双盲剂量调整至2.5 mg每日三次。
- 长期安全性分析集为双盲期随机并接受研究药物、且在长期扩展中继续研究药物的所有患者,统计分析为描述性。
主要发现
- 主研究121例患者中87例(72%)进入长期扩展,其中利奥西胍-利奥西胍组42例,安慰剂-利奥西胍组45例。
- 87例中女性65例(75%)、男性22例(25%),白人62例(71%)。
- 87例中82例(94%)发生不良事件,其中66例(76%)为轻中度严重程度。
- 间质性肺病患者中肺部相关严重不良事件未增加。
临床怎么用
- 原文未据此给出推荐。
局限性
- 本研究为开放标签扩展研究,缺乏对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The phase 2b Riociguat Safety and Efficacy in Patients with Diffuse Cutaneous Systemic Sclerosis (RISE-SSc) trial investigated riociguat versus placebo in early diffuse cutaneous systemic sclerosis. The long-term extension evaluated safety and exploratory treatment effects for an additional year. METHODS: Patients were enrolled to RISE-SSc between Jan 15, 2015, and Dec 8, 2016. Those who completed the 52-week, randomised, parallel-group, placebo-controlled, double-blind phase were eligible for the long-term extension. Patients originally assigned to riociguat continued therapy (riociguat-riociguat group). Those originally assigned to placebo were switched to riociguat (placebo-riociguat group), adjusted up to 2·5 mg three times daily in a 10-week, double-blind dose-adjustment phase, followed by an open-label phase. Statistical analyses were descriptive. Safety including adverse events and serious adverse events was assessed in the long-term safety analysis set (all patients randomly assigned and treated with study medication in the double-blind phase who continued study medication in the long-term extension). The RISE-SSc trial is registered with ClinicalTrials.gov, NCT02283762. FINDINGS: In total, 87 (72%) of 121 patients in the main RISE-SSc study entered the long-term extension (riociguat-riociguat, n=42; placebo-riociguat, n=45). 65 (75%) of 87 patients were women, 22 (25%) were men, and 62 (71%) were White. Overall, 82 (94%) of 87 patients in the long-term extension had an adverse event; most (66 [76%] of 87) were of mild to moderate severity, with no increase in pulmonary-related serious adverse events in patients with interstitial lung disease. INTERPRETATION: No new safety signals were observed with long-term riociguat in patients with early diffuse cutaneous systemic sclerosis. Study limitations include the absence of a comparator group in this open-label extension study. FUNDING: Bayer and Merck Sharp & Dohme.
引用
- Distler O, Allanore Y, Denton CP, et al. Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial. Lancet Rheumatol. 2023. PMID: 38251533. doi:10.1016/S2665-9913(23)00238-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。